RIVER trial is the largest study assessing the efficacy and safety of the anticoagulant rivaroxaban in patients with an artificial mitral valve to correct an irregular heart rhythm
November 18, 2020
Rivaroxaban is Comparable to Warfarin for Bioprosthetic Mitral Valves and AF
November 18, 2020 — The primary results from the RIVER Trial, Rivaroxaban for Valvular Heart disease and Atrial…
Read More
Black patient being tested for COVID-19 using a nasal swab PCR test. black adults with COVID-19 were far more likely to be hospitalized than their white counterparts according to data from the AHA COVID-19 Cardiovascular Disease Registry. #AHA #AHA20 #AHA2020 #COVID19 #SARSCoV2
November 18, 2020
COVID-19 Cardiovascular Registry Details Disparities Among Hospitalized Patients
November 18, 2020 -- A new American Heart Association (AHA) collaborative model for COVID-19 (SARS-CoV-2) research,…
Read More
November 17, 2020
TAVR Is Now Dominant Form of Aortic Valve Replacement in the United States
November 17, 2020 — Since the approval of the first transcatheter aortic valve replacement (TAVR) device in 2011, more…
Read More
oston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge transcatheter aortic valve replacement (TAVR) system. It also initiated a global, voluntary recall of all unused inventory of the Lotus Edge due to complexities associated with the product delivery system. 
Dave Fornell, Editor
November 17, 2020
Boston Scientific Pulls Lotus Edge TAVR Valve Off The Market
November 17, 2020 — Boston Scientific Corp. announced today it is immediately retiring the entire Lotus Edge…
Read More
Women’s Heart Attack Research Program (HARP) shows combining OCT and cardiac MRI can detect the underlying cause of heart attack in women who did not have blocked arteries
November 17, 2020
OCT Combined with MRI Can Identify Cause of Unexplained Heart Attacks in Women
November 17, 2020 — Diagnostic imaging techniques were able to find the underlying cause of heart attack in many women…
Read More
Omega-3 fish oil supplements did not help patients after a heart attack in AHA 2020 study. #AHA #AHA20 #AHA2020. Getty Images
November 17, 2020
Omega-3s Do Not Reduce Cardiac Events in Recent Heart Attack Survivors
November 17, 2020 — A daily dose of omega-3 fatty acids did not reduce the risk of cardiac events, including secondary…
Read More
The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study evaluated the detection of silent, or previously undiagnosed, atrial fibrillation (AF) in moderate-risk individuals using the FDA-cleared Zio by iRhythm ambulatory monitoring patch. The results support the clinical value of early screening and targeted detection in moderate-risk populations. #AHA #AHA20 #AHA2020
November 16, 2020
Wearable Heart Monitor Detects Previously Undiagnosed Atrial Fibrillation to Prevent Hospitalizations, Stroke and Death
November 16, 2020 — The three-year clinical outcomes of the mHealth Screening to Prevent Strokes (mSToPS) study…
Read More
Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
November 16, 2020
Ticagrelor Not Superior to Clopidogrel in Reducing Heart Attacks During PCI
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to…
Read More
The Medtronic SEEQ mobile cardiac telemetry system, pictured here, and the Icentia CardioSTAT cardiac rhythm monitoring device both found in reased rates of post-operative atrial fibrillation in the SEARCH-AF trial presented at the American Heart Association annual meeting. #AHA #AHA20 #AHA2020
November 16, 2020
Patients at Risk of AF May Need Extra Monitoring After Heart Surgery
November 16, 2020 — Atrial fibrillation (AF), an irregular heartbeat that can increase the likelihood of stroke, was…
Read More
The Medtronic Arctic Front cryoballoon balloon was used a a front-line treatment of AF in the EARLY-AF trial. It was found to be better than anti-arrhythmic drugs in preventing the recurrence of abnormal heart rhythm (atrial tachyarrhythmia, atrial fibrillation), and improve patient well-being.  #AHA #AHA2020 #AHA20
November 16, 2020
Early Invasive Intervention for Atrial Fibrillation May Improve Patient Outcomes and Provide a Better Quality of Life
November 16, 2020 – Doctors from the Montreal Heart Institute (MHI) presented new data that shows catheter ablation as…
Read More
The AHA 2020 late-breaking SAMSON Trial found side effects reported from statins are real, but appear due to the psychological rather than the pharmacological effects of the cholesterol lowering drugs. #AHA20 #AHA2020
November 16, 2020
Side Effects Attributed to Statins Same for Those Taking a Placebo
November 16, 2020 — Among patients who stopped taking their cholesterol-lowering statin medication due to side effects…
Read More
New Novartis Data for Inclisiran Shows Effective and Sustained LDL-C Reduction at 17 Regardless of Age or Gender. Getty Images.
November 16, 2020
New Novartis Data for Inclisiran Shows Effective and Sustained LDL-C Reduction at 17 Regardless of Age or Gender
November 16, 2020 — Novartis announced results from two pooled post-hoc analyses of Phase III ORION-9, -10 and -11…
Read More
The FDA-Cleared XO Score is different. XO Score technology allows users to convert basic angioplasty balloons in the hospital's existing inventory into sophisticated scoring, cutting, and infusion/delivery devices. 
November 13, 2020
New Angioplasty System Dilates Calcified and Fibrotic Vessels
November 13, 2020 — The new U.S. Food and Drug Administration (FDA) cleared XO Score system was successfully used to…
Read More
Dia's LVivo artificial intelligence software can help automate many features of echocardiograms to speed workflow and aid novice users. The software is now integrated into the Konica Minolta Exa PACS.
November 12, 2020
Expanded AI-based Echocardiography Analysis and Reporting Added to Konica Minolta Exa Cardio PACS 
November 12, 2020 – Konica Minolta Healthcare Americas Inc. and DiA Imaging Analysis Ltd. jointly announce the expanded…
Read More
Figure 1: PROTECT III found, when compared to intra-aortic balloon pump (IABP), Impella use led to a 29% reduction in MACCE at 90 days.
November 12, 2020
Largest Study of Hemodynamically Supported High-Risk PCI Patients Finds More Complete Revascularization With Impella
November 12, 2020 — Abiomed recently announced new PROTECT III study data that demonstrates reduced rates of MACCE (…
Read More
The impact of COVID-19 on the heart and cardiovascular system is being evaluated in a new clinic for post-COVID patients to monitor and manage their cardiac recovery.
November 10, 2020
Cedars-Sinai Launches Clinic to Manage Long-Term Heart Health Issues in COVID-19 Patients
November 10, 2020 — The Smidt Heart Institute at Cedars-Sinai Hospital in Los Angeles has established a specialized…
Read More
NIH trial, the Outcomes Related to COVID-19 treated with Hydroxychloroquine among Inpatients with symptomatic Disease (ORCHID), showed no difference in deaths between placebo and hydroxychloroquine. Getty Images
Dave Fornell, Editor
November 09, 2020
Hydroxychloroquine Does Not Help Hospitalized COVID-19 Patients
November 9, 2020 — A National Institutes of Health (NIH) clinical trial evaluating the safety and effectiveness of…
Read More
SCCT Releases New Guidelines for Cardiology and Radiology Trainees in Cardiovascular CT
November 09, 2020
SCCT Releases New Guidelines for Cardiology and Radiology Trainees in Cardiovascular CT
November 6, 2020 — The Society of Cardiovascular Computed Tomography (SCCT) has released a new training guideline,…
Read More
An example of radiation dose tracking software from Imalogix showing data on cath lab angiography cases at RSNA 2019. Photo by Dave Fornell
Dave Fornell, Editor
November 04, 2020
Medical Imaging Radiation Levels in U.S. Dropped Over Past Decade
More than a decade ago, there was an alarming, rapid rise in ionizing radiation exposure in the U.S. population that…
Read More
The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Ranger Drug-coated Balloon, developed for the treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA).  
November 03, 2020
FDA Clears Boston Scientific Ranger Drug-coated Balloon
November 3, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Ranger Drug-coated…
Read More
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now